Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2002

01-02-2002

A Phase II Trial of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – Southwest Oncology Group Study

Authors: Robert P. Whitehead, Joseph M. Unger, Lawrence E. Flaherty, Eric H. Kraut, Glenn M. Mills, Catherine E. Klein, Robert A. Chapman, Gary C. Doolittle, Neel Hammond, Vernon K. Sondak

Published in: Investigational New Drugs | Issue 1/2002

Login to get access
Metadata
Title
A Phase II Trial of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – Southwest Oncology Group Study
Authors
Robert P. Whitehead
Joseph M. Unger
Lawrence E. Flaherty
Eric H. Kraut
Glenn M. Mills
Catherine E. Klein
Robert A. Chapman
Gary C. Doolittle
Neel Hammond
Vernon K. Sondak
Publication date
01-02-2002
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 1/2002
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1014484821460

Other articles of this Issue 1/2002

Investigational New Drugs 1/2002 Go to the issue

OriginalPaper

The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: a Southwest Oncology Group Study

OriginalPaper

A Phase II Trial of Bryostatin-1 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

Instructions for Authors

Instructions for Authors

OriginalPaper

Partial Circumvention of P-Glycoprotein-Mediated Multidrug Resistance by Doxorubicin-14-O-Hemiadipate

OriginalPaper

Phase II Trial of Topotecan by Continuous Infusion in Patients with Advanced Soft Tissue Sarcomas, a SWOG Study

OriginalPaper

Lack of in Vitro – in Vivo Correlation of a Novel Investigational Anticancer Agent, SH 30
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits